The topic of diabetes in pregnancy encompasses the pregnancy of women with any form of diabetes (mainly type 1 or type 2 diabetes) diagnosed prior to conception (pregestational diabetes), as well as forms of diabetes and hyperglycemia diagnosed during pregnancy. Among the latter, the most frequent form is gestational diabetes, usually diagnosed during the second trimester of gestation, and less common are early pregnancy hyperglycemia due to undiagnosed pregestational type 2 or monogenic diabetes and early onset gestational diabetes. Exposure to hyperglycemia during pregnancy, regardless of the diagnosis, is a fast-growing challenge for women and their offspring, professionals and healthcare systems worldwide [1] .
1 diabetes, despite better glucose control since conception [6] . It is well established that pregnancy planning is key to minimize unfavorable pregnancy outcomes in women with pregestational diabetes. The aim of pregnancy planning is to achieve, prior to conception, optimal glucose control (HbA1c < 6.5% or 48 mmol/mol, with low frequency of hypoglycemia), adequate supplementation of folic acid (4-5 mg/day), management of diabetes, diabetes complications and/or comorbidities that can be safely maintained throughout pregnancy, e.g., shifting women from oral agents to insulin and prescribing antihypertensives that can be used during pregnancy [7, 8] . Unfortunately, a low proportion of women with pregestational diabetes takes advantage of pregnancy planning (less than 50%), with the majority of pregnancies being unplanned [7, 8] . In real life the majority of women with diabetes have negative conditions for the start of a pregnancy [9] . Programs to promote pregnancy planning in women with pregestational diabetes have proven effective in increasing the rate of planned pregnancy and cost-effective in decreasing the costs of caring for high-risk pregnancies and offspring with perinatal morbidity or longterm disabilities [10, 11] .
Gestational diabetes (GDM) is one of the most common complications of pregnancy worldwide, with 5-20% of newborns being offspring of mothers with diagnosed or undiagnosed GDM [12] . If not timely diagnosed and effectively treated, GDM is associated with an increased risk of adverse pregnancy outcomes for both the mother and the fetus/newborn, including preeclampsia, prematurity, cesarean section, macrosomia and neonatal hypoglycemia [13] . The wide range of GDM rates reported in different countries depends on the background susceptibility to type 2 diabetes, access to care, screening policies and degree of compliance to GDM screening by healthcare professionals caring for pregnant women and, not least, differences in diagnostic criteria [12] . The issue of which criteria to use for the diagnosis of GDM has created confusion for several decades, but has now been overcome by the pragmatic approach suggested by the FIGO [1] , recognizing that any degree/form of hyperglycemia might have an impact on the newborn. In women with GDM, the exposure of the fetus to hyperglycemia starts usually beyond the ninth week of gestation (first trimester) when most of the organogenesis is completed; therefore, GDM should not affect the rate of congenital malformations. However, nowadays a large proportion of women with GDM is overweight or obese and obesity per se is associated with an increased rate of congenital malformations and acts in synergy with GDM to increase the risk of adverse pregnancy outcomes [14] . The impact of subtle alterations in glucose and other metabolites on fetal development is the field of active research.
Insulin is the only recommended treatment for hyperglycemia during pregnancy. Although there is insufficient evidence to recommend any oral medications [15, 16] , many guidelines worldwide list metformin and/or glyburide as alternative options to insulin. Metformin for the treatment of GDM has been tested in RCTs with reassuring long-term follow-up of the offspring [17, 18] . On the other hand, there are still significant concerns about the use of glyburide to treat GDM, because of increased rate of unfavorable neonatal outcomes compared to metformin or insulin and lack of long-term data on the offspring [19] .
Several approaches have been proposed to prevent GDM in women at increased risk, including lifestyle changes (diet and exercise), and use of supplements, either prior to pregnancy or during the first trimester of pregnancy [20] [21] [22] . However, at the moment no strong conclusions can be drawn with regard to the best intervention for preventing GDM.
The diagnosis of GDM also affects women well beyond pregnancy. Women with a pregnancy complicated with GDM have a sevenfold increased risk of developing type 2 diabetes in the years following childbirth and are more susceptible to cardiovascular events [23] [24] [25] . Unfortunately, the predictive value of GDM is unlikely recognized in practice, not prompting referral of these women to prevention programs aiming at decreasing the risk of both type 2 diabetes and CVD.
The purpose of this Topical Collection is to host original and review articles addressing the fast-growing challenges, research and understanding posed by the exposure to hyperglycemia during pregnancy. Professionals and healthcare systems worldwide need to increase their awareness about all different aspects of hyperglycemia and related metabolic abnormalities in pregnancy to shape the health of future generations. The goal to improve pregnancy outcomes in women with pregestational diabetes through careful pregnancy planning and in women with gestational diabetes through sustainable policies of screening and treatment should be in reach of most health care systems, being also widely supported by international health organizations. Furthermore, we should not miss the opportunity to put in place effective strategies to prevent diabetes and CVD in women with a history of GDM and to optimize health and growth of their children.
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